SCYNEXIS to Participate in Upcoming Investor Conferences
JERSEY CITY, N.J., Sept. 01, 2026 (ZM NEWSWIRE) — SCYNEXIS, Inc. (Nasdaq: SCYX), a clinical-stage biotechnology company focused on developing innovative therapies for severe and difficult-to-treat diseases with significant unmet medical need, today announced that the company will participate in the following investor conferences:
- 12th Cantor Global Healthcare Conference in New York City
Fireside chat: Friday, September 11, 2026, at 9:45 a.m. ET.
- H.C. Wainwright 28th Annual Global Investment Conference in New York City
1×1 investor meetings: September 14-16, 2026
A live webcast of the Cantor fireside chat will be available here. A replay will be available for 90 days following the event.
About SCYNEXIS
SCYNEXIS, Inc. (NASDAQ: SCYX) is a clinical-stage biotechnology company focused on developing innovative therapies for severe and difficult-to-treat diseases with significant unmet medical need. SCY-770 is being developed for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) and has been granted Orphan Drug designation. SCYNEXIS’s proprietary antifungal platform “fungerps” includes BREXAFEMME® (ibrexafungerp tablets), the first approved representative of this novel class, which has been licensed to GSK, and SCY-247, currently in clinical stages of development. For more information, visit www.scynexis.com
CONTACT:
Investor Relations
John Fraunces
LifeSci Advisors
Tel: 917-355-2395
jfraunces@lifesciadvisors.com
Publication Partner: ZM Newswire – Powered By Zeest Media
This press release is provided by the issuer. The statements and opinions expressed are those of the author and do not necessarily reflect the views of Zeest Media.
© 2026 Zeest Media. All rights reserved.
